GlaxoSmithKline Weighted Average Shares Trend from 2010 to 2020

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

GlaxoSmithKline PLC Weighted Average Shares is decreasing with slightly volatile movements from year to year. Weighted Average Shares is predicted to flatten to about 2.5 B. For the period between 2010 and 2020, GlaxoSmithKline PLC, Weighted Average Shares quarterly trend regression had mean deviation of 464,607,873 and r-value of (0.42). GlaxoSmithKline PLC Revenues is increasing as compared to previous years. The last year's value of Revenues was reported at 33.75 Billion. The current Research and Development Expense is estimated to increase to about 4.7 B, while Cost of Revenue is estimated to decrease to under 11.4 B.

Search Historical Trends

 
Refresh
Check GlaxoSmithKline PLC financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Direct Expenses of 10 B, Consolidated Income of 4.6 B or Cost of Revenue of 11.4 B, as well as many exotic indicators such as Interest Coverage of 158, Long Term Debt to Equity of 2.7 or Calculated Tax Rate of 23.02. This can be a perfect complement to check GlaxoSmithKline PLC Valuation or Volatility. It can also complement various GlaxoSmithKline PLC Technical models. Please check the analysis of GlaxoSmithKline PLC Correlation with competitors.

GlaxoSmithKline Weighted Average Shares Marginal Breakdown

Showing smoothed Weighted Average Shares of GlaxoSmithKline PLC with missing and latest data points interpolated. The weighted average number of shares or units issued and outstanding that are used by the company to calculate [EPS]; determined based on the timing of issuance of shares or units in the period.
View

2.49 B

10 Years Trend
Decreasing
Slightly volatile
 Weighted Average Shares 
      Timeline 

GlaxoSmithKline Weighted Average Shares Regression Statistics

Arithmetic Mean 5,045,343,302
Geometric Mean 4,948,000,939
Coefficient Of Variation 16.94
Mean Deviation 464,607,873
Median 5,355,297,232
Standard Deviation 854,607,287
Range 2,907,595,969
R-Value(0.42)
R-Squared 0.17
Significance 0.20
Slope(107,484,808)

GlaxoSmithKline Weighted Average Shares Over Time

20105.2 B
20115.2 B
2012B
20135.4 B
20145.3 B
20155.4 B
20165.4 B
20175.4 B
20185.4 B
20195.4 B
20202.5 B

Other Fundumenentals of GlaxoSmithKline PLC

About GlaxoSmithKline PLC Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include GlaxoSmithKline PLC income statement, its balance sheet, and the statement of cash flows. GlaxoSmithKline PLC investors use historical funamental indicators, such as GlaxoSmithKline PLC's Weighted Average Shares, to determine how well the company is positioned to perform in the future. Although GlaxoSmithKline PLC investors may use each financial statement separately, they are all related. The changes in GlaxoSmithKline PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GlaxoSmithKline PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on GlaxoSmithKline PLC Financial Statements. Understanding these patterns can help to make the right decision on long term investment in GlaxoSmithKline PLC. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Receivables5.67 B6.08 B6.87 B5.97 B
Inventories5.56 B5.48 B5.95 B5.09 B
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 99437 people.

Current Sentiment - GSK

GlaxoSmithKline PLC Investor Sentiment

Predominant part of Macroaxis users are currently bullish on GlaxoSmithKline PLC. What is your judgment towards investing in GlaxoSmithKline PLC? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of GlaxoSmithKline PLC Correlation with competitors. Please also try Equity Search module to search for activelly-traded equities including funds and etfs from over 30 global markets.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page